

- \* Only pre-registered guests can enter the JHVS exhibition. Please register online in advance.
- \* Pre-registration is required for joining the partnering event. Please create your online account in advance. We provide a matching account after the registration.



JAPAN  
HEALTHCARE VENTURE  
SUMMIT 2024

Invitation  
Letter

Oct. 9(Wed)-11(Fri), 2024 Pacifico Yokohama

Organizers

Ministry of Health, Labour and Welfare  
(Venture Support Strategy Office, Policy Planning Division for Pharmaceutical Industry Promotion and Medical Information Management, Health Policy Bureau)

Co-located Events



BioJapan 2024



Regenerative  
Medicine  
Japan 2024



healthTECH  
JAPAN 2024

Cooperation



Learn more ▶

Japan Healthcare Venture Summit 2024



<https://mediso.mhlw.go.jp/jhvs2024/en/index.html>

## Overview of the event

Japan is one of the few countries in the world that creates new drugs, and while it has high potential for innovation, such as excellent basic research in academia and manufacturing technology possessed by SMEs, it has been pointed out that it has not always been able to fully utilize this potential. In particular, ventures (medical ventures) that aim to commercialize pharmaceuticals, medical devices, regenerative medicine, and other products are required to fully demonstrate their capabilities and lead medical innovation in Japan as in Europe and the United States.

In December 2023, the government held the "Council of the Concept for Early Prevalence of the Novel Drugs to Patients by Improving Drug Discovery Capabilities," and after 5 rounds of discussion, the interim report was released in May 2024. In this interim report, it was proposed that a public-private council be established to promote initiatives while attracting not only domestic stakeholders but also foreign companies to build a drug discovery ecosystem. In response, a roadmap for measures up to 2028 was decided at the Gate Opening Summit for Innovative Drug Discovery held in July.

In February 2024, the Ministry of Health, Labour and Welfare launched the "Project Team on Healthcare Startup Acceleration, Ministry of Health, Labour and Welfare, Japan" and published the final report on June 27. Based on the roadmap decided at the Gate Opening Summit for Innovative Drug Discovery and the recommendations in this final report, we will work on measures to promote the practical application of excellent seeds and establish a virtuous cycle (ecosystem) that fosters medical ventures.

To further accelerate this, we will hold the "Japan Healthcare Venture Summit 2024" in Pacifico Yokohama, continuing from last year. At the summit, we will provide a place for medical ventures to promote matching and networking with key persons from major companies, financial institutions, research institutions, etc., by exhibiting booths and holding presentations, etc., and create an environment for stakeholders to deepen their understanding of the current state of regulations and related systems and venture support initiatives.

We hope that medical ventures and academia who have seeds that are expected to lead to innovative pharmaceuticals, medical devices, regenerative medicine, and other products will participate in this summit, and that it will be a place to step up toward practical application.

## Exhibitor List

<b>A</b> aiwell Inc.	CUES Consulting Inc.	Japanese Pharma Open Innovation Programs	PharmaBio Corporation
Alchemedicine, Inc.	CyDing Co., Ltd.	ASKA Pharmaceutical Co., Ltd.	Pharmaceuticals and Medical Devices Agency
AnGes Inc.	Cytoronix Inc.	DAIICHI SANKYO CO., Ltd.	PhotoQ3 Inc.
EmendoBio Inc.	<b>E</b> Epistra Inc.	Mitsubishi Tanabe Pharma Corporation	PRD Therapeutics, Inc.
Ascenion GmbH	Epsilon Molecular Engineering, Inc.	JIC Venture Growth Investments Co., Ltd.	PuREC Co., Ltd.
AT CO., LTD.	Expression Technologies (Kagawa University)	Jiksak Bioengineering, Inc.	PURMX Therapeutics, Inc.
AutoPhagyGO Inc.	<b>F</b> FullStem Co. Ltd.	JOCAVIO Co. Ltd.	ReMI Co. Ltd.
Axil Capital Advisors K.K.	FunPep Co., Ltd.	<b>K</b> K Pharma, Inc.	Rena Therapeutics, Inc.
<b>B</b> BD Fund	<b>G</b> Gel Coat Biomaterials, Inc.	Keio Innovation Initiative, Inc.	RIN Institute Inc.
Biomy Inc.	GEXVal Inc.	Knowledge Palette, Inc.	<b>S</b> S & K Biopharma, Inc.
<b>C</b> C4U Corporation	Globe Ltd.	Kringle Pharma, Inc.	SAMURAI Biotech Association
CarbGeM Inc.	Greater Tokyo Innovation Ecosystem (GTIE)	<b>L</b> LTT Bio-Pharma Co., Ltd.	SANSHO Co., Ltd.
CellGenTech, Inc	University of Tokyo	Luna RD co., Ltd.	SAPALA CO., LTD.
Cellusion Inc.	Waseda University	<b>M</b> M Bio Technology Inc.	SCAD (Stem Cell & Device Laboratory, Inc.)
Clinical Innovation Network (CIN)	Tokyo Institute of Technology, etc.	MEDICOLAB Co., Ltd.	Faculty of Medicine, Kyoto University
Clinical Research Core Hospitals	Green BioMed Inc	MEDISO Medical Innovation Support Office	Kyoto University Hospital
Hokkaido University Hospital	<b>H</b> Healthcare Innovation Hub	miiBio, Inc.	SEEDSUPPLY INC.
Tohoku University Hospital	HiPep Laboratories	Mitsubishi UFJ Capital Co., Ltd.	SENTAN Pharma Inc.
National Cancer Center Hospital East	Holo4Med	MOLCURE Inc.	SHIGA UNIVERSITY OF MEDICAL SCIENCE
Chiba University Hospital	Human Life CORD Japan Inc.	momotato-gene Inc.	SleepWell Inc.
National Cancer Center Hospital	<b>I</b> iHeart Japan Corporation	<b>N</b> NANO MRNA Co., Ltd.	TAGCyx Biotechnologies Inc.
The University of Tokyo Hospital	Infirmax Inc.	NATIAS Inc.	TAK-Circulator Co.
Juntendo University Hospital	Inner Resource, Inc.	National Institutes of Biomedical Innovation, Health and Nutrition	The University of Tokyo Edge Capital Partners (UTEC)
Keio University Hospital	iXgene Inc.	Neko Pharma Co., Ltd	TOHOKU UNIVERSITY
Nagoya University Hospital	<b>J</b> JAAME	Nihon BioData Corporation	Tohoku University Knowledge Cast Co., Ltd.
Kyoto University Hospital	Japan Science and Technology Agency	Nobelpharma Co., Ltd.	TOHOKU University Venture Partners Co., Ltd.
Osaka University Hospital	FerropoCure Inc.	Noile-Immune Biotech Inc.	University of Tsukuba T-CREDO
Kobe University Hospital	Medicinal Chemistry Pharmaceutical, Co.,Ltd.(MCP)	NOVIUS Company, LTD.	<b>U</b> Veritas In Silico Inc.
Okayama University Hospital	Rebirthel Co., Ltd.	<b>O</b> Ohsugi BioPharma Consulting Co., Ltd.	<b>W</b> Willsame Inc.
Kyushu University Hospital	Rege Nephro Co., Ltd.	OSAKA University Venture Capital Co., LTD.	GRIT Partners Law Offices
Nagasaki University Hospital	SONIRE Therapeutics Inc.	<b>P</b> PancTherapy, Inc.	
Clinical Research Innovation and Education Center Tohoku University Hospital	TOKIWA-Bio Inc.	Periotherapia Co., Ltd.	
CLOVERNA Inc.		Perseus Proteomics Inc.	

As of Sep. 13, 2024

## JHVS Stage Events

Please check the website for the latest information including each schedule.  
<https://mediso.mhlw.go.jp/jhvs2024/en/index.html>

### JHVS SHOWCASE

Exhibitors will give a 90-second introduction of their business to create partnering opportunities during JHVS. Archived presentations will be available for a limited period of time after the session on JHVS website.

**Date** Oct. 9 (Wed.) - Oct. 11 (Fri.)

### The Future Envisioned by Women Entrepreneurs: Challenges and Visions for Global Expansion

This panel discussion will share the experiences of current female entrepreneurs and their visions for promoting global expansion.

**Date** Oct. 9 (Wed.)

### AMED×MEDISO Collaboration Program ~AMED Seeds Acceleration Pitch~

Seeds accelerated by AMED will be introduced and VCs will comment on the evaluation of each seed. Networking will be held after the pitches.

**Date** Oct. 9 (Wed.)

### JHVS Venture Awards 2024

"JHVS Venture Awards 2024" is an awards event selection committee aimed at promoting the spirit of challenge in medical ventures and the creation of innovations.

**Date** Oct. 10 (Thu.)

## Access

### Location

Pacific Convention Plaza Yokohama (PACIFICO Yokohama)  
 1-1-1, Minato Mirai, Nishi-ku, Yokohama 220-0012, JAPAN  
 TEL: +81-45-221-2155 URL: <https://www.pacifico.co.jp/english>

### Access by train

- From Tokyo Station: Take a train on the JR Tokaido Line, transfer to the Minato Mirai Line at Yokohama Station.
- From Shibuya Station: Take a limited express train (through to the Minato Mirai Line) on the JR Tokyu Toyoko Line.
- From Shinjuku Station: Take a train on the JR Shonan-Shinjuku Line, transfer to the Minato Mirai Line at Yokohama Station.
- From Shin-Yokohama Station: Take a train on the JR Yokohama Line, get off at Kikuna Station, change to an express train on the Tokyu Toyoko Line bound for Motomachi-Chukagai (Chinatown), and get off at Minato Mirai Station.

## Contact

Japan Healthcare Venture Summit 2024 Secretariat  
 JTB Communication Design, Inc.

3-23-1 Shiba, Minatoku, Tokyo 105-8335 Celestine-Shiba Mitsui-Building 12F  
 Email : [jhvs2024@jtbcom.co.jp](mailto:jhvs2024@jtbcom.co.jp)  
 URL : <https://mediso.mhlw.go.jp/jhvs2024/en/index.html>

We ask for your cooperation in preventing the spread of COVID-19.

### MEDISO-JHVS Alumni

This is a networking event aimed at connecting ventures. JHVS visitors and exhibitors, MEDISO consulting venture supporters, and others are also expected to attend.

**Date** Oct. 10 (Thu)

### Challenges Surrounding Drug Discovery and the Creation of a Global Drug Discovery Ecosystem

This event will showcase Japan's measures to strengthen its drug discovery capabilities and future perspectives on drug discovery, with a focus on the creation of a global drug discovery ecosystem.

**Date** Oct. 10 (Thu)

### Global Fundraising: Real Stories of Overseas Venture Capital Fundraising

This panel discussion will share experiences and expertise from domestic start-ups who are carrying out or attempting to raise funds from overseas venture capitals.

**Date** Oct. 10 (Thu)

### Clinical Research Core Hospital x MEDISO Collaboration Project: The Future of Clinical Trials in the Startup Ecosystem

With a new start-up support system in place and a period of change ahead, this panel discussion will focus on the role of core clinical research hospitals in clinical trials conducted by start-ups.

**Date** Oct. 10 (Thu)

## Venue Layout

Partnering Area

